-
16:40
-
16:20
-
16:00
-
15:40
-
15:20
-
15:00
-
14:40
-
14:20
-
14:00
-
13:30
-
13:00
-
12:30
-
12:00
-
11:30
-
11:00
-
10:40
-
10:20
-
10:00
-
09:40
-
09:20
-
09:00
-
08:40
-
08:20
-
08:00
-
07:30
-
07:00
Morocco achieves groundbreaking success in reprogramming blood cells into stem cells
Moroccan researchers have successfully reprogrammed blood cells into induced pluripotent stem cells (iPSCs) for the first time, marking a significant milestone in medical science for the country. The Mohammed VI Foundation for Science and Health announced the achievement, which could position Morocco as a regional leader in stem cell research and regenerative medicine.
A national platform for innovation
The Mohammed VI Foundation revealed that this breakthrough will serve as a foundation for building a national platform dedicated to cell reprogramming and differentiation. This platform is expected to support biomedical research, personalized medicine, and the development of advanced treatments for critical diseases.
The Director of the Mohammed VI Center for Research and Innovation highlighted that this success reflects Morocco’s commitment to advancing medical research and innovation in the region.
The power of induced pluripotent stem cells
iPSCs are revolutionary because of their ability to grow indefinitely and differentiate into almost any type of cell in the body. Their creation requires only a small blood sample, enabling scientists to model human diseases, test new drugs, and develop regenerative therapies tailored to individual patients.
These cells offer transformative possibilities in medicine, including repairing vital organs like the heart, brain, liver, and lungs, as well as advancing immunotherapy against cancers.
A global perspective on iPSCs
Since their discovery in 2006 by Japanese researcher and Nobel Prize winner Shinya Yamanaka, iPSCs have revolutionized medical research worldwide. They are being used to model diseases, explore regenerative treatments, and conduct clinical trials for degenerative diseases, eye disorders, and blood-related conditions.
Japan remains a global leader in the field, pioneering clinical trials for Parkinson’s disease, spinal cord injuries, and age-related vision loss. The United States and Europe are advancing iPSC-based drug testing and personalized medicine, while China has emerged as a key player, investing heavily in stem cell and biotechnology research.
Morocco’s achievement in successfully reprogramming blood cells into iPSCs places the country on the global map of stem cell innovation and opens the door to groundbreaking medical advancements in the region.
